Literature DB >> 27259014

Distinct Clinicopathologic and Genetic Features of 2 Histologic Subtypes of Intrahepatic Cholangiocarcinoma.

Akimasa Hayashi1, Kento Misumi, Junji Shibahara, Junichi Arita, Yoshihiro Sakamoto, Kiyoshi Hasegawa, Norihiro Kokudo, Masashi Fukayama.   

Abstract

Previous studies have identified 2 clinically significant morphologic subtypes of intrahepatic cholangiocarcinoma (ICC) on the basis of anatomic location and/or histologic appearances. Recognizing that these classification schemes are not always applicable practically, this study aimed to establish a novel classification system based on mucin productivity and immunophenotype and to determine the rationale of this classification by examining the clinicopathologic and genetic characteristics of the 2 subtypes defined by this method. We retrospectively investigated 102 consecutive ICC cases and classified them on the basis of mucin productivity and immunophenotype (S100P, N-cadherin, and NCAM). We found that 42 and 56 cases were classified as type 1 and type 2 ICCs, respectively, and only 4 cases were of indeterminate type. Type 1 ICC, generally characterized by mucin production and diffuse immunoreactivity to S100P, arose less frequently in chronic liver diseases and showed higher levels of serum CEA and CA 19-9 than did type 2 ICC, which generally showed little mucin production and exhibited immunoreactivity to N-cadherin and/or NCAM. Type 1 ICC was characterized by several pathologic features, including higher frequencies of perineural invasion and lymph node metastasis. Although the log-rank test demonstrated that type 1 ICC had significantly worse survival, the multivariate Cox regression analysis showed no prognostic significance of this histologic subtype. Genetic analyses revealed that KRAS mutation was significantly more frequent in type 1 ICC, whereas IDH mutation and FGFR2 translocation were restricted to type 2 ICC. In conclusion, the present classification of ICC based on mucin productivity and immunophenotype identified 2 subtypes with clinicopathologic significance.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27259014     DOI: 10.1097/PAS.0000000000000670

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  28 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

2.  A proposal of imaging classification of intrahepatic mass-forming cholangiocarcinoma into ductal and parenchymal types: clinicopathologic significance.

Authors:  Hyungjin Rhee; Myeong-Jin Kim; Young Nyun Park; Chansik An
Journal:  Eur Radiol       Date:  2018-12-17       Impact factor: 5.315

3.  Predicting IDH mutation status of intrahepatic cholangiocarcinomas based on contrast-enhanced CT features.

Authors:  Yong Zhu; Jun Chen; Weiwei Kong; Liang Mao; Wentao Kong; Qun Zhou; Zhengyang Zhou; Bin Zhu; Zhongqiu Wang; Jian He; Yudong Qiu
Journal:  Eur Radiol       Date:  2017-07-27       Impact factor: 5.315

4.  Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas.

Authors:  Masayuki Akita; Kohei Fujikura; Tetsuo Ajiki; Takumi Fukumoto; Kyoko Otani; Takeshi Azuma; Tomoo Itoh; Yonson Ku; Yoh Zen
Journal:  Mod Pathol       Date:  2017-03-24       Impact factor: 7.842

5.  Subtype Classification of Intrahepatic Cholangiocarcinoma Using Liver MR Imaging Features and Its Prognostic Value.

Authors:  Sungeun Park; Youngeun Lee; Haeryoung Kim; Mi Hye Yu; Eun Sun Lee; Jeong Hee Yoon; Ijin Joo; Jeong Min Lee
Journal:  Liver Cancer       Date:  2022-03-30       Impact factor: 12.430

6.  Intrahepatic Cholangiocarcinomas Have Histologically and Immunophenotypically Distinct Small and Large Duct Patterns.

Authors:  Carlie S Sigel; Esther Drill; Yi Zhou; Olca Basturk; Gokce Askan; Linda M Pak; Efsevia Vakiani; Tao Wang; Thomas Boerner; Richard K G Do; Amber L Simpson; William Jarnagin; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2018-10       Impact factor: 6.394

7.  EVI1 expression is associated with aggressive behavior in intrahepatic cholangiocarcinoma.

Authors:  Mariko Tanaka; Junji Shibahara; Shumpei Ishikawa; Tetsuo Ushiku; Teppei Morikawa; Aya Shinozaki-Ushiku; Akimasa Hayashi; Kento Misumi; Atsushi Tanaka; Hiroto Katoh; Kei Sakuma; Takashi Kokudo; Yoshinori Inagaki; Junichi Arita; Yoshihiro Sakamoto; Kiyoshi Hasegawa; Masashi Fukayama
Journal:  Virchows Arch       Date:  2018-10-23       Impact factor: 4.064

8.  Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review.

Authors:  Audra N Boscoe; Catherine Rolland; Robin Kate Kelley
Journal:  J Gastrointest Oncol       Date:  2019-08

9.  A new pathological classification of intrahepatic cholangiocarcinoma according to protein expression of SSTR2 and Bcl2.

Authors:  Shoko Yamashita; Yuji Morine; Satoru Imura; Tetsuya Ikemoto; Yu Saito; Chie Takasu; Shinichiro Yamada; Kazunori Tokuda; Shohei Okikawa; Katsuki Miyazaki; Takeshi Oya; Koichi Tsuneyama; Mitsuo Shimada
Journal:  World J Surg Oncol       Date:  2021-05-07       Impact factor: 2.754

10.  ITGB6-Knockout Suppresses Cholangiocarcinoma Cell Migration and Invasion with Declining PODXL2 Expression.

Authors:  Yurie Soejima; Miho Takeuchi; Nao Miyamoto; Motoji Sawabe; Toshio Fukusato
Journal:  Int J Mol Sci       Date:  2021-06-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.